Latest Articles
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer - PMLiVE
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 18, 2024, 7 a.m.
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer - Reuters
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer Reuters
Published: June 17, 2024, 7 a.m.
FDA Expands Durvalumab Label to Endometrial Cancer - Medscape
FDA Expands Durvalumab Label to Endometrial Cancer Medscape
Published: June 17, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
In Memory Of Dr. Michael Brodherson - Endometriosis Foundation of America - The Blossom
In Memory Of Dr. Michael Brodherson Endometriosis Foundation of America - The Blossom
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer - PMLiVE
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!